RT Journal Article
SR Electronic
T1 Estimation of secondary household attack rates for emergent SARS-CoV-2 variants detected by genomic surveillance at a community-based testing site in San Francisco
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.01.21252705
DO 10.1101/2021.03.01.21252705
A1 Peng, James
A1 Mann, Sabrina A
A1 Mitchell, Anthea M
A1 Liu, Jamin
A1 Laurie, Matthew T.
A1 Sunshine, Sara
A1 Pilarowski, Genay
A1 Ayscue, Patrick
A1 Kistler, Amy
A1 Vanaerschot, Manu
A1 Li, Lucy M.
A1 McGeever, Aaron
A1 Chow, Eric D.
A1 Team, IDseq
A1 Marquez, Carina
A1 Nakamura, Robert
A1 Rubio, Luis
A1 Chamie, Gabriel
A1 Jones, Diane
A1 Jacobo, Jon
A1 Rojas, Susana
A1 Rojas, Susy
A1 Tulier-Laiwa, Valerie
A1 Black, Douglas
A1 Martinez, Jackie
A1 Naso, Jamie
A1 Schwab, Joshua
A1 Petersen, Maya
A1 Havlir, Diane
A1 DeRisi, Joseph
YR 2021
UL http://medrxiv.org/content/early/2021/03/03/2021.03.01.21252705.abstract
AB Background Sequencing of the SARS-CoV-2 viral genome from patient samples is an important epidemiological tool for monitoring and responding to the pandemic, including the emergence of new mutations in specific communities.Methods SARS-CoV-2 genomic sequences were generated from positive samples collected, along with epidemiological metadata, at a walk-up, rapid testing site in the Mission District of San Francisco, California during November 22-December 2, 2020 and January 10-29, 2021. Secondary household attack rates and mean sample viral load were estimated and compared across observed variants.Results A total of 12,124 tests were performed yielding 1,099 positives. From these, 811 high quality genomes were generated. Certain viral lineages bearing spike mutations, defined in part by L452R, S13I, and W152C, comprised 54.9% of the total sequences from January, compared to 15.7% in November. Household contacts exposed to “West Coast” variants were at higher risk of infection compared to household contacts exposed to lineages lacking these variants (0.357 vs 0.294, RR=1.29; 95% CI:1.01-1.64). The reproductive number was estimated to be modestly higher than other lineages spreading in California during the second half of 2020. Viral loads were similar among persons infected with West Coast versus non-West Coast strains, as was the proportion of individuals with symptoms (60.9% vs 64.1%).Conclusions The increase in prevalence, relative household attack rates, and reproductive number are consistent with a modest transmissibility increase of the West Coast variants; however, additional laboratory and epidemiological studies are required to better understand differences between these variants.Summary We observed a growing prevalence and elevated attack rate for “West Coast” SARS-CoV-2 variants in a community testing setting in San Francisco during January 2021, suggesting its modestly higher transmissibility.Competing Interest StatementDr. DeRisi is a scientific advisor to The Public Health Company, Inc., and Allen & Co.Funding Statement: JLD and this work was supported by the UCSF COVID Fund, the National Institutes of Health [UM1AI069496], the Chan Zuckerberg Biohub, the Chan Zuckerberg Initiative, and a group of private donors. SS is supported by F31 F31AI150007, JL, and ML were supported by the UCSF COVID fund. The BinaxNOW cards were provided by the California Department of Public Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UCSF Committee on Human Research determined that the study met criteria for public health surveillance. All participants provided informed consent for dual testing.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenomic sequences have been deposited in GISAID. https://www.gisaid.org